摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-溴-N-苯基烟酰胺 | 313562-28-6

中文名称
5-溴-N-苯基烟酰胺
中文别名
——
英文名称
5-bromo-N-phenylnicotinamide
英文别名
5-bromo-N-phenylpyridine-3-carboxamide
5-溴-N-苯基烟酰胺化学式
CAS
313562-28-6
化学式
C12H9BrN2O
mdl
MFCD00806104
分子量
277.12
InChiKey
OLCNIPQERCZMGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    314.0±27.0 °C(Predicted)
  • 密度:
    1.559±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    16
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    42
  • 氢给体数:
    1
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2933399090

反应信息

  • 作为反应物:
    描述:
    2-苯基噻吩5-溴-N-苯基烟酰胺potassium phosphate 、 silver hexafluoroantimonate 、 dichloro(pentamethylcyclopentadienyl)rhodium (III) dimer 、 copper diacetate 作用下, 以 1,4-二氧六环 为溶剂, 反应 24.0h, 以35%的产率得到5-bromo-N-phenyl-2-(5-phenylthiophen-2-yl)nicotinamide
    参考文献:
    名称:
    Rh(III)-Catalyzed Amide-Directed Cross-Dehydrogenative Heteroarylation of Pyridines
    摘要:
    A new catalytic methodology has been developed for the synthesis of heteroaryled pyridines via a rhodium(III)-catalyzed dehydrogenative cross-coupling reaction. This protocol features a good substrate scope with a broad range of functional group tolerance and high regioselectivity of the pyridyl C-H activation.
    DOI:
    10.1021/ol403311b
  • 作为产物:
    描述:
    5-溴烟酸苯胺 在 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 19.0h, 生成 5-溴-N-苯基烟酰胺
    参考文献:
    名称:
    通过上调 IL-10 治疗炎症性肠病的新型 CDK8 抑制剂的发现和抗炎活性评估
    摘要:
    增加抗炎细胞因子白细胞介素 10 (IL-10) 水平是抑制包括炎症性肠病 (IBD) 在内的致病性炎症进展的有前景的策略。由于细胞周期蛋白依赖性激酶 8 (CDK8) 抑制可以上调活化的髓源性树突状细胞中的 IL-10 丰度,因此它被认为是 IBD 治疗的有效靶点。在这里,描述了作为抗炎剂的新型 CDK8 抑制剂的完整发现过程。从汉黄芩素开始,全面开展基于结构的优化和构效关系(SAR)研究,然后是先导化合物85(N-(2-乙基苯基)-5-(4-(哌嗪-1-羰基)苯基)烟酰胺)被开发为一种有效的药物样 CDK8 抑制剂,可同时上调 IL-10体内和体外。此外,化合物85(CDK8 IC 50 = 56 nM,IL-10 增强率 88%)在 IBD 动物模型中表现出有效的抗炎活性。这些结果证实了某些CDK8抑制剂可用作有效的抗IBD药物。
    DOI:
    10.1021/acs.jmedchem.2c00356
点击查看最新优质反应信息

文献信息

  • Substituted piperidines as Par-1 Antagonists
    申请人:Jeske Mario
    公开号:US20120046268A1
    公开(公告)日:2012-02-23
    The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumour disorders.
    这项发明涉及新型取代哌啶,以及它们的制备方法,它们用于治疗和/或预防疾病,以及用于制备用于治疗和/或预防疾病的药物,特别是心血管疾病和肿瘤疾病。
  • NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES
    申请人:Hoffmann-La Roche Inc.
    公开号:US20130143863A1
    公开(公告)日:2013-06-06
    The invention provides novel compounds having the general formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A 1 , A 2 , A 3 , A 4 , A 5 and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful, for example, as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrome.
    这项发明提供了具有一般式(I)的新化合物,其中R1、R2、R3、R4、R5、R6、A1、A2、A3、A4、A5和n如本文所述,包括这些化合物的组合物以及使用这些化合物的方法。这些化合物可用作醛固酮合酶(CYP11B2或CYP11B1)抑制剂,用于治疗或预防慢性肾脏疾病、充血性心力衰竭、高血压、原发性醛固酮增多症和库欣综合征。
  • Nicotinamide derivative or salt thereof
    申请人:Fujiwara Hideyasu
    公开号:US08772320B2
    公开(公告)日:2014-07-08
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R1 represents a halogen atom; R2 represents a C1-12 alkyl group, a C2-12 alkenyl group, a C2-12 alkynyl group, a C3-8 cycloalkyl group, an aryl group, an ar-C1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R4 and R5 each independently represent a hydrogen atom; and R2 and R4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异Syk抑制活性的化合物和药物组合物。本发明提供了以下式子(I)所表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每个都可以选择性地具有至少一个取代基;R3表示芳基或杂环基,每个都可以选择性地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起选择性地形成一个带有至少一个取代基的环状氨基团)或其盐,以及用于治疗Syk相关疾病的药物组合物,其包括该烟酰胺衍生物或其盐。
  • Substituted piperidines as Par-1 antagonists
    申请人:Jeske Mario
    公开号:US08987248B2
    公开(公告)日:2015-03-24
    The invention relates to novel substituted piperidines, to processes for their preparation, to their use for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular of cardiovascular disorders and tumor disorders.
    本发明涉及新型取代哌啶,其制备方法,其用于治疗和/或预防疾病的用途,以及用于制备治疗和/或预防疾病的药物,特别是心血管疾病和肿瘤疾病。
  • NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF
    申请人:FUJIWARA Hideyasu
    公开号:US20130116430A1
    公开(公告)日:2013-05-09
    An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. The present invention provides a nicotinamide derivative represented by the following formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl group, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each optionally having at least one substituent; R 3 represents an aryl group or a heterocyclic group each optionally having at least one substituent; and R 4 and R 5 each independently represent a hydrogen atom; and R 2 and R 4 may form a cyclic amino group optionally having at least one substituent together with the nitrogen atom to which they bind) or a salt thereof, and a pharmaceutical composition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
    本发明的目的是提供一种具有优异的Syk抑制活性的化合物和制药组合物。本发明提供了一种由以下式(I)表示的烟酰胺衍生物(其中R1表示卤素原子;R2表示C1-12烷基、C2-12烯基、C2-12炔基、C3-8环烷基、芳基、芳基-C1-6烷基或杂环基,每种均可选地具有至少一个取代基;R3表示芳基或杂环基,每种均可选地具有至少一个取代基;R4和R5各自独立地表示氢原子;且R2和R4可以与它们结合的氮原子一起形成具有至少一个取代基的环状氨基团)或其盐,并且用于治疗Syk相关疾病的制药组合物包括该烟酰胺衍生物或其盐。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐